Cel The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients. These gene expression signatures will be utilised clinically as non-invasive diagnostic tests for PD. The sensitivity of the newly developed diagnostic test will be determined by extensive validations on independent cohort of PD patients, whereas the specificity will be assessed by testing patients with atypical parkinsonisms, including multiple system atrophy, progressive supranuclear palsy and diffuse Lewy body disease. In order to test the specificity of the diagnostic set in other disorders that affect basal ganglia, Huntington's disease and dopa responsive dystonia patients will be analysed. The second objective of the proposal is to determine correlations between gene expression signatures and different stages of PD and thus provide the basis for early diagnosis and monitoring of disease progression. These changes in blood gene expression will be correlated with alterations detected by neuroimaging in the brain of PD patients. Such combinations of molecular and morphological markers of disease may ultimately facilitate the selection and monitoring of neuroprotective therapies for PD. Finally, GENEPARK aims to develop new bioinformatic software tools for selection of genomic biomarkers using microarray data. A set of established computational tools will be applied and novel methods, some of them based on mechanistic modelling of the neurodegenerative diseases, will be developed in order to study the advantages and limitations of the different methodologies. With special emphasis on careful clinical selection of patients and sufficient power regarding patient numbers, as well as extensive quality control and validation of the data, GENEPARK aims to develop a standardised approach to development and validation of haemogenomic biomarkers of disease. Dziedzina nauki natural sciencesbiological sciencesgeneticsnatural sciencescomputer and information sciencessoftwaremedical and health sciencesbasic medicineneurologyparkinson Program(-y) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Temat(-y) LSH-2005-1.2.2-2 - Development of innovative methods for diagnosis of nervous system disorders Zaproszenie do składania wniosków FP6-2005-LIFESCIHEALTH-6 Zobacz inne projekty w ramach tego zaproszenia System finansowania STREP - Specific Targeted Research Project Koordynator UNIVERSITY MEDICAL CENTER LJUBLJANA Wkład UE Brak danych Adres Zaloska cesta 2 LJUBLJANA Słowenia Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (7) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko UNIVERSITY OF LUEBECK Niemcy Wkład UE Brak danych Adres Ratzeburger Allee 160 LUEBECK Zobacz na mapie Koszt całkowity Brak danych MEDITERANEAN INSTITUTE FOR LIFE SCIENCES Chorwacja Wkład UE Brak danych Adres Mestrovicevo setaliste bb SPLIT Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych PROGENIKA BIOPHARMA S.A. Hiszpania Wkład UE Brak danych Adres Parque Tecnologico Zamudio, 801-B DERIO Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych EBERHARD-KARLS-UNIVERSITY TUEBINGEN Niemcy Wkład UE Brak danych Adres Wilhelmstr. 5 TUEBINGEN Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych TEL AVIV UNIVERSITY Izrael Wkład UE Brak danych Adres Ramat Aviv 39040 TEL AVIV Zobacz na mapie Koszt całkowity Brak danych RR & CO. PODJETJE ZA POSLOVNE STORITVE, D.O.O. Słowenia Wkład UE Brak danych Adres Dunajska cesta 20 LJUBLJANA Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Francja Wkład UE Brak danych Adres 101 rue de Tolbiac PARIS Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych